Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, it targets lysine-specific demethylase 1 (LSD1), a key enzyme in gene regulation implicated in disease progression. Its lead candidates include iadademstat (ORY-1001), a selective LSD1 inhibitor in Phase II trials for acute myeloid leukemia and small cell lung cancer, and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor in Phase II for psychiatric and neurological conditions like borderline personality disorder. The pipeline also features ORY-3001 in preclinical stages for non-oncological diseases and emerging programs such as ORY-4001, a selective HDAC6 inhibitor. Oryzon Genomics S.A. emphasizes personalized medicine, biomarker identification, and strategic partnerships to advance its compounds through Phase II, positioning it as a European leader in epigenetic innovation within oncology and CNS therapeutics. Led by co-founder Carlos Manuel Buesa Arjol as Chairman, CEO, and President, the company maintains a robust advisory board of oncology and CNS experts.